3rd Quarter - Report
CSL BEHRING LLC for CSL BEHRING LLC
Firm
Client
Income
—
Expenses
$180,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN R. BULLARD | Sr. Manager, Federal Government Affairs |
| PATRICK COLLINS | Director, Healthcare Policy and External Affairs |
| DENNIS JACKMAN | Senior Vice President, Healthcare Policy & External Affairs |
Health Issues HCR
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN R. BULLARD | Sr. Manager, Federal Government Affairs |
| PATRICK COLLINS | Director, Healthcare Policy & External Affairs |
| DENNIS JACKMAN | Senior Vice President, Healthcare Policy & External Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.